SecBot SecBot

CMND

Clearmind Medicine Inc.
Nasdaq· Pharmaceutical Preparations· Inc. Z4· CIK 0001892500 Biotech & Drug Discovery
$6.12 +0.25 (+4.28%)
Oct 26 4:00 PM ET · prev $5.87
Market cap
$3.0M
Nano cap
1 year
−99.8%
from $3,200.00 · Oct 27
30 days
−2.9%
from $6.30
52-week range
$5.72–3,200.00
−100% from high · low Oct 2
Avg volume 20D
23.8K
Oct 7 spike 146.4K
Short interest
14.8K
≈2.9% of shares · −58.5%
Days to cover
1.0
at average volume
Insider net
+$211.8K
1 buyer · 1 seller · 12 mo
Filing reports
44
analyzed by SecBot
SecBot read MIXED 17 reports · 90 days
Balance 2 bearish · 5 bullish · 1 mixed · 9 neutral oldest → newest, height = score
Avg score ·High conf. 7/17
Strongest BEARISH Clearmind Medicine issued a notice to CLA Investors to sell $2,000,000 in convertible promissory notes at a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $330.3K. 1 insider sold $118.5K.

  • Short sellersCOVERING

    Short interest −58.5% to 14.8K shares. 1.0 days to cover, ≈2.9% of shares.

  • TrendDOWNTREND

    30% below its 50-day average.

Who's buying

13F
Top holderSharesValue
HRT FINANCIAL LP35,143$77.0K
MORGAN STANLEY700$1.5K
ROYAL BANK OF CANADA287$1.0K

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 SEC
Clearmind Medicine issued a notice to CLA Investors to sell $2,000,000 in convertible promissory notes at a 10%…
6-K — Impact 6/10
Oct 13, 2026 SEC
Clearmind Medicine's 51%-owned subsidiary Charging Robotics launched a next-generation automated EV-charging platform…
6-K — Impact 3/10
Oct 8, 2026 SEC
Clearmind Medicine announced the publication of a patent application in Japan covering 3-MMC-based treatment for…
6-K — Impact 3/10
Oct 5, 2026 Trading halt
Halt Resumed: CMND — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-02T23:50:00.000Z | Resumed 2026-10-05T13:00:00.000Z
Sep 23, 2026 Press
Clearmind Medicine announced the U.S. publication of three patent applications covering novel combinations of LSD…
Impact 3/10
Sep 17, 2026 Press
Clearmind Medicine's Chief of Global Impact presented insights from the company's clinical trial at Yale and Johns…
Impact 2/10
Jun 16, 2026 Insider
HRT FINANCIAL LP sold 22,139 shares
10%+ Owner @ $3.31 ($73.2K)
Jun 15, 2026 Insider
HRT FINANCIAL LP sold 3,183 shares
10%+ Owner @ $3.32 ($10.6K)

Insider ledger

Form 4
$330.3K
bought · 1 insider
$118.5K
sold · 1 insider
DateInsiderTypeValue
Jun 16, 2026
HRT FINANCIAL LP
10%+ Owner
SELL$73.2K
Jun 15, 2026
HRT FINANCIAL LP
10%+ Owner
SELL$10.6K
Jun 12, 2026
HRT FINANCIAL LP
10%+ Owner
SELL$7.1K
Jun 11, 2026
HRT FINANCIAL LP
10%+ Owner
SELL$27.7K
Jun 10, 2026
HRT FINANCIAL LP
10%+ Owner
BUY$330.3K

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
14,819
shares short
-58.5%
vs prior settlement
1.0
days to cover
≈2.9%
of shares outstanding
Trading halts
Oct 2, 2026Resumption ScheduledResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 5, 2026
Trading halt
Halt Resumed: CMND — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-02T23:50:00.000Z | Resumed 2026-10-05T13:00:00.000Z
Oct 2, 2026
Trading halt
Trading Halt: CMND — T1 (News Pending)
Clearmind Medicine Inc. Cmn | Market: NASDAQ | Code: T1 — News Pending
Oct 2, 2026
Trading halt
Trading Halt: CMND — T3 (News and Resumption Times)
Clearmind Medicine Inc. Cmn | Market: NASDAQ | Code: T3 — News and Resumption Times
Sep 23, 2026
Announcement
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and…
Sep 17, 2026
Announcement
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind’s clinical trial at…

SecBot reports

44 filings · 19 press releases · 6 bullish · 9 bearish · 3 mixed · 26 neutral
All CMND filing & press-release reports (63)